MedPath
NMPA Approval

Fexofenadine Hydrochloride Oral Suspension

国药准字H20249766

December 25, 2024

Drug Information

盐酸非索非那定口服混悬液

口服混悬剂

120ml:0.72g

化学药品

December 25, 2024

Company Information

Applicant Company

广州市萝岗区开源大道196号自编1-2栋

Manufacturing Company

长沙市浏阳经济技术开发区健康大道1号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

盐酸非索非那定口服混悬液 - NMPA 批准文号 | MedPath